The number of amoxicillin products on back order has increased to between two and three dozen oral presentations of amoxicillin.

As of December 8, 2022, most drugmakers could not estimate a resupply date of amoxicillin, but Teva Pharmaceuticals has released the dates of January and February 2023, and Hikma Pharmaceuticals short-dated their allocated supply for August 2023.

The worsening supply issue could be connected to the surge in viral infections even though amoxicillin is not a recommended treatment for COVID-19, flu, or respiratory syncytial virus (RSV) infections. Amoxicillin is not recommended to treat RSV cases, but some physicians will prescribe antibiotics when they are not medically necessary.

The original drug shortage may have sent a ripple effect through amoxicillin/clavulanate products - the recommended backup treatment for some infections if amoxicillin is not available - because 29 of them were in short supply as of late November 2022.

To obtain your own copy of the November 2022 FDA Guidance "Compounding Certain Beta-Lactam Products Under Section 504A of the Federal Food, Drug and Cosmetic Act," go to:

Compounding Certain Beta-Lactam Products in Shortage Under Section 503A of the Federal Food Drug and Cosmetic Act | FDA

The following updated table lists amoxicillin formulas on the CompoundingToday.com website, along with some formulas for acetaminophen preparations which have also been reported in short supply in some areas.

*A letter preceding the number designates the General Formula Section.

No letter preceding the number designates the Documented Formula Section.

Also see:

https://www.fda.gov/​media/​163367/​download

Loyd V. Allen, Jr., PhD, RPh
Editor-in-Chief
International Journal of Pharmaceutical Compounding
Remington: The Science and Practice of Pharmacy Twenty-second edition